Onco-Innovations Enters LOI for Exclusive Option on LAG-3 Inhibitor Program

Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) has taken a significant step toward expanding its oncology pipeline by entering into a non-binding letter of intent (LOI) with Ifowonco Informatics Incorporated. The LOI is the first step toward negotiating a definitive agreement that would grant Onco an exclusive option on Ifowonco's proprietary small-molecule inhibitor program targeting lymphocyte-activation gene 3 (LAG-3). This move signals a strategic push into next-generation cancer immunotherapy, potentially combining oral small-molecule checkpoint inhibition with Onco's expertise in DNA damage response (DDR) therapeutics.

The proposed collaboration is designed to merge Ifowonco's oral small-molecule immune checkpoint technology with Onco-Innovations' capabilities in DDR therapeutics, translational oncology, and clinical development. The companies believe that combining DDR inhibition with LAG-3 blockade could potentially enhance anti-tumour immune responses across multiple solid tumour indications. This approach is particularly noteworthy because currently approved LAG-3 therapies are monoclonal antibodies administered intravenously, whereas Ifowonco's program focuses on developing orally available small-molecule inhibitors. This could offer advantages in patient convenience and potentially different pharmacokinetic properties.

Under the terms of the LOI, the companies intend to evaluate the LAG-3 program independently and, where supported by preclinical findings, explore its potential use alongside DDR-based therapeutic approaches, including Onco-Innovations' ONC010 program. This dual evaluation strategy could accelerate the development of combination therapies that target both the immune system and the tumour's DNA repair mechanisms, potentially improving outcomes for patients with solid tumours.

Thomas O'Shaughnessy, CEO of Onco-Innovations, expressed optimism about the potential agreement, stating that it could position the company “at the intersection of precision oncology and next-generation cancer immunotherapy.” This reflects the growing interest in combining different therapeutic modalities to overcome resistance mechanisms and improve treatment efficacy.

The news is important for investors and the biotech community as it highlights the ongoing shift toward oral small-molecule immunotherapies, which could disrupt the current market dominated by IV biologics. Additionally, the focus on combination strategies with DDR inhibitors suggests a more integrated approach to cancer treatment, potentially leading to more durable responses. For Onco-Innovations, this deal could diversify its pipeline and strengthen its position in the competitive oncology landscape.

While the LOI is non-binding and a definitive agreement is not yet in place, the announcement demonstrates the company's proactive efforts to bring innovative therapies to the clinic. Investors will be watching for further developments, including preclinical data and the finalization of the agreement. For more details, the full press release is available at https://ibn.fm/E63Ne.